Cytiva and Fida Biosystems have joined forces to expand analytical capabilities for protein research.
The collaboration combines Cytiva’s Biacore surface plasmon resonance (SPR) systems with Fidabio’s in-solution Flow-Induced Dispersion Analysis (FIDA) technology, providing both a complementary and an orthogonal approach that gives scientists a more complete picture of molecular interactions.
By linking structural details — such as protein size and stability — with precise binding and interaction data, researchers can make faster, more confident decisions earlier in development.
The collaboration will result in the following benefits:
- Unified insight: SPR and FIDA together provide orthogonal data for a fuller understanding of complex molecules
- Better decisions, sooner: accelerates research on challenging targets such as bispecific antibodies and degraders
- Simplified workflows: adds depth without adding complexity.
Brian Sørensen, CEO, Fida Biosystems, said: "Combining technologies with Cytiva fosters deeper insight, giving researchers greater confidence in their results."
"This collaboration supports our mission to advance biophysical analysis and empower scientists with faster, more informative data for complex molecular research."
Tim Bervoets, President, Discovery & Medical, Cytiva, added: "Researchers need to understand how their molecules behave and they need that insight quickly."
"Pairing Biacore SPR with FIDA measurements gives them a more complete picture, without adding complexity."
"It’s a practical step forward that supports confident decisions and keeps workflows moving. In essence, it helps accelerate the researcher’s time to insight.”
Fidabio’s technology provides both complementary and orthogonal data to the Biacore SPR system’s data, providing critical information on the quality of the sample.
By combining two methods, researchers can link structural information, such as protein size and stability, with detailed binding and interaction data.
This combined view helps accelerate research on complex molecules, including bispecific antibodies and degraders, while also improving confidence in experimental results.
This partnership reflects Cytiva’s and Danaher’s shared mission to advance analytical science, enable confident, data-driven discoveries and improve lives through innovation.